| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||
| Acetyl-L-carnitine (ALC, ALCAR) — an endogenous acetylated derivative of L-carnitine that participates in the carnitine/acylcarnitine system for shuttling acyl groups between cellular compartments and buffering mitochondrial acetyl-CoA/CoA balance. A naturally occurring molecule involved in mitochondrial energy metabolism. It is a small-molecule nutrient/“mitochondrial co-factor” used clinically or as a supplement in various jurisdictions, with mechanistic relevance to fatty-acid oxidation flux control and (context-dependent) support of cytosolic acetyl-CoA pools that feed lipid synthesis and protein acetylation. In oncology contexts, its relevance is primarily metabolic (substrate handling and acetyl unit trafficking) plus supportive-care use cases rather than a validated anticancer drug modality. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral dosing produces measurable systemic exposure with reported Tmax on the order of hours and plasma half-life on the order of hours in small human PK studies; tissue distribution depends on carnitine transporters (e.g., OCTN2) including across the blood–brain barrier. Systemic levels achievable with typical supplementation are generally far below the high millimolar exposures sometimes used in in-vitro cancer studies, so concentration-driven cytotoxic claims often have limited translational relevance unless a mechanism is triggered at low exposure or via compartmental flux effects. In-vitro vs systemic exposure relevance: Many reported “direct anticancer” effects occur at supraphysiologic concentrations and may not map to achievable plasma/tissue levels; flux-level effects on acetyl-group trafficking and FAO may be more relevant at physiologic ranges but are strongly context-dependent (tumor type, ACLY/ACSS2 status, nutrient environment). Clinical evidence status: Supportive-care evidence is mixed and indication-specific; a large randomized trial found no benefit for taxane-related chemotherapy-induced peripheral neuropathy at 12 weeks and worsening at longer follow-up, arguing against routine use for CIPN prevention. Evidence for cancer-related fatigue/cachexia has been explored (often as L-carnitine class rather than ALCAR specifically) with meta-analytic conclusions generally not supporting efficacy in lower-bias trials. -ALC supports mitochondrial energy metabolism by transporting fatty acids into mitochondria.-Antioxidant effects: Reduces oxidative stress and lipid peroxidation. -In cancer patients with fatigue or cachexia (wasting), ALC can improve energy metabolism and physical function. -Acetyl-L-carnitine (ALC or ALCAR) levels are often reduced in Alzheimer's disease (AD) — especially in the brain and cerebrospinal fluid (CSF). -ALC is present at high concentrations in the brain -Carnitine is important in the β-oxidation of fatty acids and the acetyl portion can be used to maintain acetyl-CoA levels -ALC is active in cholinergic neurons, where it is involved in the production of acetylcholine -ALC significantly reduces Aβ-induced cytotoxicity, protein oxidation and lipid peroxidation in a concentration-dependent manner. -ALC can cause an increase in the level of ADAM10 Acetyl-L-carnitine: mechanistic pathway ranking in cancer contexts
| |||||||||||||||||||||||||||||||||||||||||||||||||
| Source: |
| Type: |
| Also known as CP32. Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death. As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression. Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy. Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent. On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer. Procaspase-3 is a apoptotic marker protein. Prognostic significance: • High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers. • Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers. |
| 5320- | ALC, | l-Carnitine: An adequate supplement for a multi-targeted anti-wasting therapy in cancer |
| - | in-vivo, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:350 Target#:42 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid